Stability and a promising acquisition

Another quarter with strong growth in Q2e

Elekta AB: 1 director

A director at Elekta AB bought 113,633 shares at 48.343SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Positive sales momentum in Q2e

CMD: Innovation meets margin accretion

Arjo AB: 1 director

A director at Arjo AB bought 100,000 shares at 32.750SEK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Bonesupport Holding AB: 1 director

A director at Bonesupport Holding AB bought 2,000 shares at 273.000SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

New CEO appointed

Strong quarter and an attractive valuation

Strong gross margin but soft on orders

The power of M&A compounding: Part II

Continued positive order momentum in Q4e

MedCap AB: 2 directors

A director at MedCap AB sold 50,000 shares at 444.000SEK and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Still in wait-and-see mode

Returning to organic growth

Arjo (Hold, TP: SEK35.00) - Soft start to 2025

Q1 sales were broadly in line, but adj. EBITDA was c8% below our forecast and c6% below consensus. The main differences came from higher operating expenses than expected as well as a slightly lower gross margin. Product sales were weak, but service/spare parts and rental saw stronger sales than expected, a mix that is generally negative for the margin trend. We reiterate our HOLD and have cut our target price to SEK35 (42).

Vimian (Buy, TP: SEK55.00) - 2025 off to a good start

Q1 sales were largely in line with our forecast and consensus, while adj. EBITA beat by c8% and c6%, respectively. Margin gains were reported across business lines, also outperforming expectations. However, demand for expensive elective orthopaedic procedures remained muted in the US, although we expect it to come back from H2. We reiterate our BUY and SEK55 target price.

Margin pressure in '25e

Sales growth set to accelerate

Heading in the right direction